EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

An antisense oligonucleotide targeting the heat‐shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis

Pierre-Marie Boutanquoi, Lenny Pommerolle, Lucile Dondaine, Julie Tanguy, Pierre-Simon Bellaye, Léo Biziorek, Marine Gautier-Isola, Bernard Mari, Denis Masnikov, Palma Rocchi, Pascal Finetti iD, Patricia Korczak und 6 weitere

British Journal of Pharmacology · 2025

DOI: 10.1111/bph.17470 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2025. Verfasst von Pierre-Marie Boutanquoi und 17 weiteren Autor:innen. Beteiligte Einrichtung: INSERM U1231, Center for Translational and Molecular Medicine, Labex LIPSTIC and Label of Excellence From La Ligue Nationale Contre le Cancer, Dijon,…. Hauptthemen laut MEDLINE: Oligonucleotides, Antisense, alpha-Crystallin B Chain, Pulmonary Fibrosis, Idiopathic Pulmonary Fibrosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Institut National Du Cancer, Agence Nationale de la Recherche, Inserm Transfert.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Purpose Idiopathic pulmonary fibrosis (IPF) is a fatal disease characterized by fibroblast activation and abnormal accumulation of extracellular matrix in the lungs. We previously demonstrated the importance of the heat shock protein α B‐crystallin (HSPB5) in TGF‐ β 1 profibrotic signalling, which suggests that HSPB5 could be a new therapeutic target for the treatment of IPF. The purpose of this study was thus to develop antisense oligonucleotides targeting HSPB5 and to study their effects on the development of experimental pulmonary fibrosis. Experimental Approach Specific antisense oligonucleotides (ASO) were designed and screened in vitro , based on their ability to inhibit human and murine HSPB5 expression. The selected ASO22 was characterized in vitro in human fibroblast CCD‐19Lu cells and A549 epithelial pulmonary cells, as well as in vivo using a mouse model of bleomycin‐induced pulmonary fibrosis. Key Results ASO22 was selected for its capacity to inhibit TGF‐ β 1‐induced expression of HSPB5 and additional key markers of fibrosis such as plasminogen activator inhibitor‐1, collagen, fibronectin and α ‐smooth muscle actin in fibroblastic human CCD‐19Lu cells as well as plasminogen activator inhibitor‐1 and α ‐smooth muscle actin in pulmonary epithelial A549 cells. Intra‐tracheal or intravenous administration of ASO22 in bleomycin‐induced pulmonary fibrotic mice decreased HSPB5 expression and reduced fibrosis, as demonstrated by decreased pulmonary remodelling, collagen accumulation and Acta2 and Col1a1 expression. Conclusion and Implications Our results suggest that an antisense oligonucleotide strategy targeting HSPB5 could be of interest for the treatment of IPF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Oligonucleotides, Antisensealpha-Crystallin B ChainPulmonary FibrosisIdiopathic Pulmonary FibrosisAnimalsHumansMiceBleomycinMice, Inbred C57BLMaleA549 CellsTransforming Growth Factor beta1Cell Line

Stichwörter der Autor:innen

HSPB5TGF‐β1antisense oligonucleotidesheat shock proteinpulmonary fibrosis

Substanzen

Oligonucleotides, Antisensealpha-Crystallin B ChainBleomycinCRYAB protein, humanTransforming Growth Factor beta1

Autor:innen und Institutionen

  • INSERM U1231, Center for Translational and Molecular Medicine, Labex LIPSTIC and Label of Excellence From La Ligue Nationale Contre le Cancer, Dijon, France.
  • UFR des Sciences de Santé, Université Bourgogne Europe, Dijon, France.
  • Centre de Référence Constitutif des Maladies Pulmonaires Rares de l'Adultes de Dijon, réseau OrphaLung, Filière RespiFil, Centre Hospitalier Universitaire, Dijon, France.
  • Centre Georges-François Leclerc, Service de médecine nucléaire, Plateforme d'imagerie et de radiothérapie précliniques, Dijon, France.
  • Université Côte d'Azur - CNRS UMR7275 - Inserm U1323, Sophia Antipolis, France.
  • Aix Marseille Univ, CNRS, CINAM, ERL INSERM U1326, CERIMED, Marseille, France.

ORCID-Profile: Pascal Finetti

Förderung

  • Institut National Du Cancer
  • Agence Nationale de la Recherche
  • Inserm Transfert
  • Ruban Rose Foundation
  • Fonds de Dotation Recherche en Santé Respiratoire
  • Fondation du Souffle
  • ISITE-BFC
  • Conseil Regional de Bourgogne

Zitieren

APA

Boutanquoi, P. M., Pommerolle, L., Dondaine, L., Tanguy, J., Bellaye, P. S., Biziorek, L., Gautier-Isola, M., Mari, B., Masnikov, D., Rocchi, P., Finetti, P., Korczak, P., Vialet, B., Barthelemy, P., Garrido, C., Bonniaud, P., Burgy, O., & Goirand, F. (2025). An antisense oligonucleotide targeting the heat‐shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis. British Journal of Pharmacology. https://doi.org/10.1111/bph.17470

Vancouver

Boutanquoi PM, Pommerolle L, Dondaine L, Tanguy J, Bellaye PS, Biziorek L, et al. An antisense oligonucleotide targeting the heat‐shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis. British Journal of Pharmacology. 2025. doi:10.1111/bph.17470

BibTeX
@article{Boutanquoi2025,
  author = {Boutanquoi, Pierre-Marie and Pommerolle, Lenny and Dondaine, Lucile and Tanguy, Julie and Bellaye, Pierre-Simon and Biziorek, Léo and Gautier-Isola, Marine and Mari, Bernard and Masnikov, Denis and Rocchi, Palma and Finetti, Pascal and Korczak, Patricia and Vialet, Brune and Barthelemy, Philippe and Garrido, Carmen and Bonniaud, Philippe and Burgy, Olivier and Goirand, Françoise},
  title = {An antisense oligonucleotide targeting the heat‐shock protein HSPB5 as an innovative therapeutic approach in pulmonary fibrosis},
  journal = {British Journal of Pharmacology},
  year = {2025},
  doi = {10.1111/bph.17470}
}
Kostenlos starten →